Biophytis Files for FDA Authorization to Begin Phase 3 Study in Sarcopenia

Biophytis, a clinical-stage biotechnology company, has submitted an application for authorization with the FDA to initiate the SARA-31 Phase 3 study in sarcopenia. The purpose of this study is to assess the effectiveness and safety of Sarconeos (BIO101) in treating sarcopenic patients who are at risk of mobility disability. The company anticipates receiving a response from regulatory authorities..